US guidelines for treatment of latent tuberculosis revised.
McCarthy
M
M
D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004338:Drug Combinations; D006801:Humans; D017410:Practice Guidelines as Topic; D011718:Pyrazinamide / Q000009:adverse effects* / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*; D014481:United States
D004338:Drug Combinations; D011718:Pyrazinamide; D012293:Rifampin